News
AstraZeneca begins Phase III trial of Covid-19 vaccine in US
AstraZeneca has expanded the clinical development of its potential Covid-19 vaccine candidate AZD1222 in the US, by initiating a Phase 3 clinical trial, dubbed...
Press Releases
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
Gilead Sciences, Inc. announced an agreement with Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
News
Sanofi provides update on Kevzara Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mga in severely...
Drug Research
Piramal Pharma to Collaboratewith Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs
Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), today announced that the company will be partnering with Epirum Bio on an...
Clinical Trials
Bayer submits vericiguat for marketing authorization in China for the treatment of chronic heart failure
Bayer announced the submission of the regulatory application seeking the approval of vericiguat in China. Vericiguat is an investigational oral, once-daily, first-in-class soluble guanylate...
Press Releases
Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, announced the closing of a $16 million Series B financing. The...
Press Releases
Avacta Expands Rapid SARS-CoV-2 Antigen Test Manufacturing Capacity
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
